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The synchronous development of malignant mesothelioma and pulmonary carcinoma is extremely rare.
In this case, an 83-year-old woman, without evidence of past asbestos exposure, developed malignant
pleural mesothelioma and pulmonary adenocarcinoma. She was discovered to have a lung lesion on an
unrelated preoperative chest X-ray. Clinical evaluation suggested primary bronchogenic malignancy. She
had a forty pack-year smoking history, but quit twenty years previously. At surgery, she had nodularity of
the pleura. Pathology revealed adenocarcinoma of the lung and suspected malignant mesothelioma
of the pleura. Malignant mesothelioma was conﬁrmed histologically at a second surgery.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Malignant mesothelioma is a rare tumor, strongly associated
with asbestos exposure.1 Pulmonary carcinoma, on the other hand,
is the leading cause of cancer death in the United States.2 Although
asbestos may also cause lung cancer, the main cause is tobacco. The
synchronous development of malignant pleural mesothelioma and
pulmonary carcinoma is very rare, with fewer than 20 cases
reported in the English-language medical literature.3 Most cases
have occurred in men, and most with previous asbestos exposure.
This is a unique case of synchronous malignant pleural meso-
thelioma and pulmonary adenocarcinoma occurring in a woman
with no demonstrable history or objective evidence of signiﬁcant
past asbestos exposure and who quit smoking twenty years
previously.2. Case history
An 83-year-old woman underwent evaluation for a left upper
lobe density discovered on a preoperative chest X-ray for right
rotator cuff repair. She was a former one-pack per day cigarette
smoker for forty years, but had quit 20 years earlier. She was
a sculptor and previously worked in the printing industry. Her past
medical history included hypertension, osteoarthritis, and hyper-
lipidemia. She had no medical history of signiﬁcant pulmonary
problem.rved.CT scanning revealed a 2-cm spiculated lesion in the left upper
lobe with surrounding ground glass opacity. There was no pleural
thickening, pleural effusion, interstitial ﬁbrosis, or signiﬁcant
adenopathy. Positron Emission Tomography (PET) scan revealed
abnormal uptake only within the left upper lobe, consistent with
primary malignancy. Bronchoscopy with biopsies was negative for
tumor cells.
The patient underwent mediastinoscopy and video-assisted
thoracoscopic surgery (VATS), ﬁnding unsuspected parietal pleural
nodules. The resected lung tissue revealed well to moderately
differentiated adenocarcinoma. Immunohistochemical staining
revealed positive reactivity to thyroid transcription factor-1 (TTF-1)
and no reactivity to estrogen receptor (ER), progesterone receptor
(PR), or gross cystic disease ﬂuid protein-15 (GCDFP-15, BRST-2).
There were no asbestos bodies or evidence of asbestosis. The tumor
was felt to be of lung origin. The pleural biopsies revealed an
epithelioid malignancy, suggestive of mesothelioma. Immunohisto-
chemical staining showed no reactivity to TTF-1, cytokeratin 20
(CK20), caudal type homeobox transcription factor-2 (CDX-2), ER,
PR or BRST-2, but positive staining to Wilms’ tumor-1 (WT-1),
calretinin, cytokeratin 5/6 (CK5/6), and faintly positive staining to
vimentin.
Because of the uncertainty of the tissue diagnoses, the patient
underwent a second VATS, with parietal pleurectomy. Pathology
conﬁrmed the presence of an epithelioid malignant mesothelioma.
Immunohistochemistry of the pleural tissue showed positive
staining to calretinin, WT-1, CK5/6, cytokeratin AE1/AE3, anti-
cytokeratin (Cam 5.2), D2-40 (membranous), and cytokeratin MNF-
116. There was no reactivity to TTF-1 or carcinoembryonic antigen
(CEA).
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asbestos bodies by scanning electron microscopy (SEM) and an
unremarkable asbestos ﬁber count.
After having undergone resection of her lung cancer, she
received combination chemotherapy, consisting of pemetrexed and
carboplatin, directed at her mesothelioma.3. Discussion
This case presented preoperatively as a primary lung cancer.
Pleural nodules were detected at the time of surgery. Lung tissue
histology conﬁrmed adenocarcinoma of the lung. The pleural
cancer, however, revealed immunohistochemical characteristics of
mesothelioma, not primary lung cancer. Repeat pleural tissue
analysis conﬁrmed malignant epithelioid mesothelioma.
Malignant mesothelioma is a rare tumor, with an estimated
incidence of 3000 per annum in the United States.4 Although
asbestos causes the vast majority of mesotheliomas in US males,
there are data suggesting a lower attributable risk to asbestos
among women.5
Malignant pleural mesothelioma and pulmonary carcinoma
occurring synchronously is an extremely rare event. The ﬁrst such
case was published in 1980.6 In 1993, Cagle et al.7 reported the
second case. Both cases occurred in individuals with signiﬁcant
past asbestos exposure and asbestosis. Since then, there have been
fewer than 20 cases reported. Attanoos et al.8 reported on six cases
from a group of 500 with mesothelioma, all with a history of
asbestos exposure. Four of the six had asbestosis. Allen and Moran9
identiﬁed threemales with synchronous pulmonary carcinoma and
malignant pleural mesothelioma from a review of over 16,000
pleuropulmonary cases.
The differentiation between pulmonary adenocarcinoma and
epithelioid malignant mesothelioma can pose difﬁculties. Pathol-
ogists frequently use batteries of immunohistochemical tests in
order to make this important distinction. In this case, such testing
indicated two distinct tumor types – an adenocarcinoma of the
lung and a diffuse malignant mesothelioma of the pleura.
In this case, there was no apparent occupational asbestos
exposure and no radiographic evidence of asbestosis or pleural
plaques. Examination of the lung showed no asbestos bodies on
light microscopy or SEM and no elevated tissue asbestos content.Tobacco represents the strongest risk factor for the development
of lung cancer.2 The risk increases with duration and amount
smoked. The risk decreases after increasing years of smoking
cessation. In this case, she had stopped smoking about twenty years
previously, thereby signiﬁcantly decreasing her risk for subsequent
lung cancer. Asbestos also causes lung cancer, although attribution
usually requires sufﬁcient cumulative exposure and adequate
latency.10
In summary, this is a unique case of malignant pleural meso-
thelioma and pulmonary adenocarcinoma occurring synchronously
in a woman without evidence for attribution for either cancer to
asbestos. Her past cigarette smoking, although remote, likely
contributed to her development of lung cancer. In this case, the
recognition of a second cancer is important regarding management
and prognosis. Furthermore, the absence of evidence for causation
by asbestos may have signiﬁcant medicolegal implications.
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